Leblond, Véronique <br/><br/>
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.  [electronic resource] 

 -  Leukemia & lymphoma  11 2017 
 - 2615-2623 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.1080/10428194.2017.1307357  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bayes Theorem<br/>Bortezomib--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Female<br/>Hematologic Diseases--chemically induced<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Remission Induction<br/>Waldenstrom Macroglobulinemia--drug therapy